References

Anttinen H, Terho EO, Myllylä R & Savolainen ER (1986) Two serum markers of collagen biosynthesis as possible indicators of irreversible pulmonary impairment in farmer’s lung. Am Rev Respir Dis 133:88-93.

de Andrade J & Kennedy JI (1999) The lung in systemic lupus erythematosus. Semin Resp Crit Care 20: 169-178.

Arden M & Adamson I (1992) Collagen synthesis and degradation during the development of asbestos induced pulmonary fibrosis. Exp Lung Res 18: 9-20.

Ashbaugh DG, Bigelow DB, Petty TL & Levine BE (1967) Acute respiratory distress in adults. Lancet 2: 319-23.

Bachella L, Tinell C, Gigè LS, Peona V, Aprile C, Gorrini M, Pastarenzi L, Cetta G & Luisetti M (1996) Serum type I and type III procollagen peptide levels in sarcoidosis. Eur Respir J 9: 1648-1651.

Bateman ED, Turner-Warwick M & Adelmann-Grill BC (1981) Immunohistochemical study of collagen types in human foetal lung and fibrotic lung disease. Thorax 36: 645-653.

Bateman ED, Turner-Warwick M, Haslam P & Adelmann-Grill BC (1983) Cryptogenic fibrosing alveolitis: prediction of fibrogenic activity from immunohistochemical studies of collagen types in lung biopsy specimens. Thorax 38: 93-101.

Bauer H & Löfgren S (1964) International study of pulmonary sarcoidosis in mass chest radiographs. Acta Med Scand 176: 103-105. (Abstract)

Becklake MR (1976) Asbestos-related diseases of the lung and other organs: their epidemiology and implications for clinical practice. Am Rev Respir Dis 114: 187-227.

Bégin R, Cantin A, Boileau R & Bisson G (1987a) Spectrum of alveolitis in quartz-exposed human subjects. Chest 92: 1061-1067.

Bégin R, Cantin A & Sebastian P (1990) Chrysotile asbestos exposures can produce an alveolitis with limited fibrosing activity in a subset of high retainer sheep. Eur Respir J 3: 81-90.

Bégin R, Martel B, Desmarais Y, Drepeau G, Boileau R, Rola-Pleszczynski M & Masse S (1986) Fibronectin and procollagen 3 levels in bronchoalveolar lavage of asbestos-exposed human subjects and sheep. Chest 89: 237-243.

Bégin R, Masse S, Rola-Pleszczynski M, Boctor M & Drapeau G (1987b) Asbestos exposure dose — bronchoalveolar milieu response in asbestos workers and the sheep model: evidences of a threshold for chrysotile-induced fibrosis. Drug Chem Toxicol 10: 87-107.

Bensadoun ES, Burge AK, Hogg JC & Roberts CR (1996) Proteoglycan deposition in pulmonary ­fibrosis. Am J Respir Crit Care Med 154: 1819-1828.

Bentsen KD, Lanng C, Horslev-Petersen K & Risteli J (1988) The aminoterminal propeptide of type III procollagen and basement membrane components in serum during wound healing in man. Acta Chir Scand 154: 97-101.

Bjermer L, Engström-Laurent A, Lundgren R, Rosenhall L & Hällgren R (1987a) Hyaluronan and type III procollagen peptide concentrations in bronchoalveolar lavage fluid as marker of disease activity in farmer’s lung. Br Med J 295: 803-806.

Bjermer L, Engström-Laurent A, Thunell M & Hällgren R (1987b) The mast cell and signs of pulmonary fibroblast activation in sarcoidosis. Int Archs Allergy Appl Immun 82: 298-301.

Bjermer L, Lundgren R & Hällgren R (1989) Hyaluronan and type III procollagen peptide concentrations in bronchoalveolar lavage fluid in idiopathic pulmonary fibrosis. Thorax 44: 126-131.

Bjermer L, Thunell M & Hällgren R (1986) Procollagen III peptide in bronchoalveolar lavage fluid. A potential marker of altered collagen synthesis reflecting pulmonary disease in sarcoidosis. Lab Invest 55: 654-656.

Bjermer L, Thunell M, Rosenhall L & Stjernberg N (1991) Endobronchial biopsy positive sarcoidosis: relation to bronchoalveolar lavage and course of disease. Resp Med 85: 229-234.

Bjoraker JA, Ryu JH, Edvin MK, Myers JL, Tazelaar HD, Schroeder DR & Offord KP (1998) ­Prognostic significance of histopathological subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 157: 199-203.

Borm P (1994) Biological markers and occupational lung disease: Mineral dust-induced respiratory disorders. Exp Lung Res 20: 457-470.

Cantin A, Boileau R & Begin R (1988) Increased procollagen III aminoterminal peptide-related antigens and fibroblast growth signals in the lungs of patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis. 137: 572-578.

Carey DE, Goldberg B, Ratzan SK, Rubin KR & Rowe DW (1985) Radioimmunoassay for type I procollagen in growth hormone-deficient children before and during treatment of growth hormone. Periatr Res 19: 8-11.

Cavalleri A, Gobba F, Bacchella L, Luberto F & Ziccardi A (1988) Serum type III procollagen peptide in asbestos workers: an early indicator of pulmonary fibrosis. Br J Ind Med 45: 818-823.

Chan ED, Worthen GS, Augustin A, Lapadat R & Riches DWH (1998) Inflammation in the pathogenesis of interstitial lung diseases. In: Schwarz MI & King TE Jr (ed) Interstitial lung disease. B.C.Decker Inc., Hamilton, p 135-161.

Chesnutt AN, Matthay MA, Tibayan FA & Clark JG (1997) Early detection of type III procollagen peptide in acute lung injury. Am J Respir Crit Care Med 156: 840-845

Churg A & Warnock M (1981) Asbestos and other ferruginous bodies: Their formation and clinical significance. Am J Pathol 102: 447-456.

Clark JG, Milberg JA, Steinberg KP& Hudson LD (1995) Type III procollagen peptide in the adult respiratory distress syndrome. Association of increased peptide levels in bronchoalveolar lavage fluid with increased risk for death. Ann Int Med 122: 17-23

Cormier Y, Laviolette M, Cantin A, Tremblay GM & Begin R (1993) Fibrogenic activities in bronchoalveolar lavage fluid of farmer’s lung. Chest 104: 1038-1042.

Costabel U, du Bois R, Eklund A, et al. (1994) Consensus conference: activity of sarcoidosis. Eur Respir J 7: 624-627.

Coultas DB, Zumwalt RE, Black WC & Sobonya RE (1994) The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 150: 967-72.

Crystal RG, Bitterman PB, Rennard SI & Keogh BA (1984) Interstitial lung disease of unknown cause. Disorders characterised by chronic inflammation of lower respiratory tract. N Engl J Med 310: 235-244.

Dail DH & Hammar SP (1994) Pulmonary Pathology, 2nd ed. Springer-Verlag, New York. 1-19, 597-678.

Davis GS (1994) Bronchoalveolar lavage in interstitial lung disease. Semin Respir Crit Care Med 15: 37-60.

Diot E, Diot P, Valat C, Boissinot E, Asquier E, Lemarie E & Guilmot J (1995) Predictive value of serum III procollagen for diagnosis of pulmonary involvement in patients with scleroderma. Eur Respir J 8: 1559-1565.

Farjanel J, Hartman D, Guidet B, Luquel L & Offenstadt G (1993) Four markers of collagen ­metabolism as possible indicators of disease in the adult respiratory distress syndrome. Am Rev Respir Dis 147: 1091-1099.

Fraser RS, Paré JAP, Fraser RG & Paré PD (1994) Synopsis of diseases of the chest. W.B. Saunders Company, Philadelphia, p 202-208.

Fujimoto K, Kubo K, Yamaguchi S, Honda T & Matsuzawa Y (1995) Eosinophil activation in patients with pulmonary fibrosis. Chest 108: 48-54.

Gilligan D, O`Connor C, Ward K, Moloney D, Bresnihan B & FitzGerald M (1990) Bronchoalveolar lavage in patients with mild and severe rheumatoid lung disease. Thorax 45: 591-596.

Harf R, Biot N, Perrin-Fayolle M, et al. (1988) Prognostic value of ACE, lysozyme and pulmonary lymphocytosis in sarcoidosis. In: Gassi C, et al.. eds. Sarcoidosis and other granulomatous disorders. Elsevier, Amsterdam, p 595-597.

Harjanne A (1984) Automated kinetic determination of angiotensin converting enzyme in serum. Clin Chem 30: 901-902.

Harrison N, McAnulty R, Haslam P, Black C & Laurent G (1990) Evidence for protein oedema, ­neutrophil influx, and enhanced collagen production in lungs of patients with systemic sclerosis. Thorax 45: 606-610.

Harrison N.K, McAnulty RJ, Kimpton WG, Fraser JRE, Laurent TC & Laurent GJ (1993) Heterogenity of type III procollagen N-terminal peptides in BAL fluid from normal and fibrotic lungs. Eur Respir J. 6: 1443-1448

Hasselbach H, Junker P, Horslev-Petersen K, Lisse I & Bentsen KD (1990) Procollagen type III aminoterminal peptide in serum in idiopathic myelofibrosis and allied conditions: relation to disease activity and effect of chemotherapy. Am J Hematol 33: 18-26.

Haukipuro K, Risteli L, Kairaluoma MI & Risteli J (1987) Aminoterminal propeptide of type III procollagen in healing wound in humans. Ann Surg 206: 752-756.

Hällgren R, Samuelsson T, Laurent TC & Modig J (1989) Accumulation of hyaluronan (hyaluronic acid) in the lung adult respiratory distress syndrome. Am Rev Respir Dis 139: 682-687.

Johnston IDA (ed) (1999) The diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults. Thorax 54 (Suppl 1): S1-S30.

Kantrow SP, Meyer KC, Kidd P & Raghu G (1998) The CD4/CD8 ratio in BAL fluid is highly variable in sarcoidosis. Eur Respir J 10: 2716-2721.

Karttunen T, Sormunen R, Risteli L, Risteli J & Autio-Harmainen H (1989) Immunoelectronmicroscopic localization of laminin, type IV collagen and type III pN-collagen in reticular fibers of human lymph nodes. J Histochem Cytochem 37: 279-286.

Katzenstein AL-A (1997) Katzenstein & Askin"s surgical pathology of non-neoplastic lung disease. W.B. Saunders Company, Philadelphia. 48-80.

Katzenstein ALA & Myers JL (1998) Idiopathic pulmonary fibrosis. Clinical relevance of pathologic classification. Am J Respir Crit Care Med 157: 1301-1315.

Kelly CA (1999) The lung in rheumathoid arthritis. Semin Resp Crit Care Med 20: 139-147.

Kikuchi K, Ihn H, Sato S, Igarashi A, Soma Y, Ishibashi Y & Takehara K (1994) Serum concentrations of procollagen type I carboxyterminal propeptide in systemic sclerosis. Arch Dermatol Res 286: 77-80.

King TE Jr (1998) Idiopathic pulmonary fibrosis. In: Schwarz MI & King TE Jr (ed) Interstitial lung disease. B.C.Decker Inc., Hamilton, p 597-644.

Kipen HM, Lilis R, Suzuki Y, Valciukas JA & Selikoff IJ (1987) Pulmonary fibrosis in asbestos insulation workers with lung cancer: A histological and histopathological evaluation. Br J Ind Med 44: 96-100.

Kirk JME, Heard BEH, Kerr I, Turner-Warwick M & Laurent GJ (1984) Quantitation of types I and III collagen in biopsy lung samples from patients with cryptogenic fibrosing alveolitis. Collagen Rel Res 4: 169-182.

Koskinen K, Zitting A, Tossavainen A, Rinne JP, Roto P, Kivekäs J, Reijula K & Huuskonen MS (1998) Radiographic abnormalities among Finnish construction, shipyard and asbestos industry workers. Scand J Work Environ & Health 24: 109-117

Kuhn III C, Boldt J, King TE, JR., Crouch E, Vartio T & McDonald JA (1989) An immunohistochemical study of architectural remodelling and connective tissue synthesis in pulmonary fibrosis. Am Rev Respir Dis 140: 1693-1703.

Kuhn C & McDonald J (1991) The role of the myofibroblast in idiopathic pulmonary fibrosis. ­Ultrastructural and immunohistochemical features of the sites of active extracellular matrix synthesis. Am J Pathol 138: 1257-1265.

Kuroki S, Ohta A, Sueoka N, Katoh O, Yamada H & Yamaguchi M (1995) Determination of various cytokines and type III procollagen aminopeptide levels in bronchoalveolar lavage fluid of the patients with pulmonary fibrosis: Inverse correlation between type III procollagen aminopeptide and interferon-γ in progressive patients. Br J Rheum 34: 31-36.

Larsson K, Eklund A, Malmberg P, Bjermer L, Lundgren R & Belin L (1992) Hyaluronic acid ­(hyaluronan) in BAL fluid distinguishes farmers with allergic alveolitis from farmers with asymptomatic alveolitis. Chest 101: 109-114.

Larsson K, Malmberg P, Eklund A, Belin L & Blaschke E (1988) Exposure to microorganisms, airway inflammatory changes and immune reactions in asymptomatic dairy farmers. Int Arch Allergy Appl Immunol 87: 127-133.

Lawrence EC, Brouseau KP, Berger MB, Kurman CC, Marcon L & Nelson DL (1988) Elevated concentrations of soluble Interleukin-2 receptors in serum samples and bronchoalveolar lavage fluids in active sarcoidosis. Am Rev Resp Dis 137: 759-764.

Low RB, Cutroneo KR, Davis GS & Giancola MS (1983) Lavage type III procollagen N-terminal peptides in human pulmonary fibrosis and sarcoidosis. Lab Invest 48: 755-759.

Low R.B, Giancola MS, King Jr TE, Chapitis J, Vacek P & Davis GS (1992) Serum and bronchoalveolar lavage of N-terminal type III procollagen peptides in idiopathic pulmonary fibrosis. Am Rev Respir Dis 146: 701-706.

Luisetti M, Bulgheroni A, Baccella L, Pasturenzi L & Aprile C (1990) Elevated serum procollagen III aminopeptide levels in sarcoidosis. Chest 98: 1414-1420.

Lynch DA (1998) Imaging of occupational lung diseases. Semin Respir Crit Care Med 19: 447-458.

Maasilta P, Salonen EM, Vaheri A, Kivisaari L, Holsti LR & Mattson K (1991) Procollagen-III in serum, plasminogen activation and fibronectin in bronchoalveolar lavage fluid during and following irradiation of human lung. Int J Radiation Oncology Biol Phys 20: 973-980.

Madri JA & Furthmayr H (1980) Collagen polymorphism in the lung. An immunochemical study of pulmonary fibrosis. Hum Pat 11: 353-366.

Marshall BG, Wangoo A, Cook HT & Shaw RJ (1996) Increased inflammatory cytokines and new collagen formation in cutaneous tuberculosis and sarcoidosis. Thorax 51: 1253-1261.

McDonald JA, Broekelman TJ, Matheke ML, Crouch E, Koo M & Kuhn III C (1986) A monoclonal antibody to the carboxyterminal domain of procollagen type I visualizes collagen synthesizing fibroblasts. J Clin Invest 78: 1237-1244.

Meduri GU, Tolley EA, Chinn A, Stentz F & Postlethwaite A (1998) Procollagen types I and III aminoterminal propeptide levels during acute respiratory distress syndrome and in response to ­methylprednisolone treatment. Am J Resp Crit Care Med 158: 1432-1441.

Melkko J, Kauppila S, Niemi S, Risteli L, Haukipuro K, Jukkola A & Risteli J (1996) Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin Chem 42: 947-954.

Melkko J, Niemi S, Risteli L & Risteli J (1990) Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem 36: 1328-1332.

Milman N, Kristensen MS, Bentsen K, Grode G & Fredriksen J (1995) Hyaluronan and procollagen type III aminoterminal peptide in serum and bronchoalveolar lavage fluid in patients with pulmonary sarcoidosis. Sarcoidosis 12: 38-41.

Miyahara M, Njieha FK & ProckopDJ (1982) Formation of collagen fibrils in vitro by cleavage of procollagen with procollagen proteinases. J Biol Chem 257: 8442-8448.

Niemelä O (1985) Radioimmunoassays for type III procollagen amino-terminal peptides in humans. Clin Chem 31: 1301-1304.

Niemelä O, Blake JE & Orrego H (1992) Serum type I collagen propeptide and severity of alcoholic liver disease. Alcohol Clin Exp Res 16: 1064-1067.

Niemelä O, Risteli J, Blake JE, Risteli L, Compton KV & Orrego H (1990) Markers of fibrogenesis and basement membrane formation in alcoholic liver disease. Relation to severity, presence of hepatitis, and alcohol intake. Gastroenterology 98: 1612-1619.

Niemelä O, Risteli L, Parkkinen J & Risteli J (1985) Purification and characterization of the N-terminal propeptide of human type III procollagen. Biochem J 232: 145-150.

Niemelä O, Risteli L, Sotaniemi EA, Stenbäck F & Risteli J (1988) Serum basement membrane and type III procollagen-related antigens in primary biliary cirrhosis. J Hepat 6: 307-314.

O`Connor C, Ward K, van Breda A, McIlgorm A, FitzGerald M (1989) Type 3 procollagen peptide in bronchoalveolar lavage fluid: poor indicator of course and prognosis in sarcoidosis. Chest 96: 339-344.

Peyrol S, Takiya C, Cordier J & Grimaud J (1986) Organization of the connective matrix of the sarcoid granuloma. Ann New York Acad Sciences 465: 268-285.

Pietinalho A, Hiraga Y, Hosoda Y, Lofroos AB, Yamaguchi M & Selroos O (1995) The frequency of sarcoidosis in Finland and Hokkaido, Japan. A comparative epidemiological study. Sarcoidosis 12: 61-67.

Pohl WR, Thompson AB, Köhn H, Losch S, Umek H, Legenstein E, Kummer F, Rennard SI & Klech H (1992) Serum procollagen III peptide levels in subjects with sarcoidosis. A 5-year follow-up study. Am Rev Respir 145: 412-417.

Poole A, Myllylä R & Davies BH (1989) Activities of enzymes of collagen biosynthesis and levels of type III procollagen peptide in serum of patients with sarcoidosis. Life Sci 45: 319-326.

Prockop DJ & Kivirikko KI (1984) Heritable diseases of collagen. N Engl J Med 311: 376-386.

Prockop DJ & Kivirikko KI (1995) Collagens: Molecular biology, disease and potentials for therapy. Ann Rev Biochem 64: 403-434.

Prockop D, Kivirikko K, Tuderman L & Guzman N (1979) The biosynthesis of collagen and its disorders [Review];. N Engl J Med 301: 13-23.

Raghu G, Striker LJ, Hudson LD & Striker GE (1985) Extracellular matrix in normal and fibrotic human lungs. Am Rev Respir Dis 131: 281-289.

Rennard S, Basset G, Lecossier D, O’Donnel KM, Pinkston P, Martin PG & Crystal RG (1986) Estimation of absolute volume of epithelial lining fluid recovered by bronchoalveolar lavage by using urea as an endogenous marker of dilution. J Appl Physiol 60: 532-538.

Risteli J, Niemi S, Trivedi P, Mowat AP &Risteli L (1988) Rapid equilibrium radioimmunoassay for the amino-terminal propeptide human type III procollagen. Clin Chem 34: 715-718.

Risteli J & Risteli L (1995) Analysing connective tissue metabolites in human serum. Biochemical, physiological and methodological aspects. J Hepat 22 (Suppl.2): 77-81.

Risteli L & Risteli J (1986) Radioimmunoassays for monitoring connective tissue metabolism. Rheumatology 10: 216-245.

Risteli L, Puistola U, Hohtari H, Kauppila A & Risteli J (1987) Collagen metabolism in normal and complicated pregnancy: changes in the aminoterminal propeptide of type III procollagen in serum. Eur J Clin Invest 17: 81-86.

Risteli L & Risteli J (1990) Non-invasive methods for detection of organ fibrosis. In Rojkind M, et al.. eds. Connective tissue in health and disease. Boca Raton, CRP Press, p 61-98

Rohde H, Langer I, Kreig T & Timpl R (1983) Serum and urine analysis of the aminoterminal procollagen peptide type III by radioimmunoassay with antibody Fab fragments. Coll Rel Res 3: 371-379.

Roman J, Young-June J, Gal A & Perez RL (1995) Distribution of extracellular matrices, matrix receptors, and transforming growth factor-B1 in humans and experimental lung granulomatous inflammation. Am J Med Sci 309(3): 124-133.

Schaberg T, Orzechowski K, Oesterling C, Lode H & Schuppan D (1994) Simultaneous measurements of collagen type-IV-related antigen and procollagen-III-N-propeptide levels in bronchoalveolar lavage. Eur Respir J 7: 1221-1226.

Schins R & Borm P (1994) Serum procollagen type III peptide in coal workers’ pneumoconiosis: A five year follow up study. Exp Lung Res 20: 445-455.

Schins R, Lamers R, Preat B & Borm P (1995) Evaluation of serum type III procollagen peptide as an exposure marker in retired coal workers. Int Arc Occup Environ Health 66: 413-419.

Schoenfeld N, Schmolke B, Fritzsche A & Loddenkemper R (1996) Lamin fragment P1 in the sera of patients with pulmonary sarcoidosis. Sarcoidosis Vasculitis & Diffuse Lung Diseases 13: 135-138.

Schwartz DA & Peterson MW (1998) Asbestosis and asbestos induced pleural fibrosis. In: Schwarz MI & King TE Jr (ed) Interstitial lung disease. B.C.Decker Inc., Hamilton, p 351-366.

Scott J, Johnston I & Britton J (1990) What causes cryptogenic fibrosing alveolitis? A case-control study of environmental exposure to dust. Br Med J 301: 1015-1017.

Sharma OP (1986) Markers of sarcoidosis activity. Chest 90: 471-473.

Selroos O (1969) The frequency, clinical picture and prognosis of pulmonary sarcoidosis in Finland. Ph.D. Thesis Univ Helsinki , Faculty of Medicine, Helsinki.

Selroos O, Pietinalho A & Fröseth B (1994) Serum procollagen III N-terminal peptide levels in sarcoidosis. Sarcoidosis 11: 84 (Abstract).

Specks U, Nerlich A, Colby TV, Wiest I & Timpl R (1995) Increased expression of type IV collagen in lung fibrosis. Am J Respir Crit Care Med 151: 1956-1964.

Stirling RG, Cullinan P & Du Bois RM (1998) Sarcoidosis. In: Schwarz MI & King TE Jr (ed) Interstitial lung disease. B.C.Decker Inc., Hamilton, p 279-323.

Straup JP, van Kamp GJ, van Maarsseveen TCMT & Stam J (1995) Biochemical parameters in BAL of sarcoidosis. Sarcoidosis 12: 51-57.

Sutinen S, Riska H, Backman R, Sutinen SH & Froseth B (1995) Alveolar lavage fluid in normal ­volunteer subjects: cytologic, immunocytochemical, and biochemical reference values. Resp Med 89(2): 85-92.

Takiya C, Peyrol S, Cordier J & Grimaud J (1983) Connective matrix organization in human pulmonary fibrosis. Virchows Arch 44: 223-240.

Taskinen EI, Tukiainen PS, Alitalo RL & Turunen JP (1994) Bronchoalveolar lavage. Cytological techniques and interpretation of the cellular profiles. Pathol Ann. 29( Pt 2): 121-155.

Teschler H, Thompson AB, Pohl WR, Konietzko N, Rennard SI & Costable U (1992) Bronchoal­veolar lavage procollagen-III-peptide in recent onset hypersensitivity pneumonitis: correlation with extracellular matrix components. Eur Respir J 6: 709-714.

Thurlbeck WM & Churg AM (1995) Pathology of the lung, 1st ed. Thieme, New York. p 589-737.

Tsutsumi T, Nagai S, Imai K, Setoyama Y, Uchiyama T & Izumi T (1994) Soluble Interleukin-2 receptor in blood from patients with sarcoidosis and idiopathic pulmonary fibrosis. Sarcoidosis 11: 102-109.

Tukiainen P, Risteli J, Salonen EM, Laitinen T & Taskinen E (1994) Procollagen-III-N-terminal ­(PIIINP) and I-C-terminal (PICP) peptides are not markers of fibrosis in sarcoidosis. Sarcoidosis 11: 84 (Abstract).

Uitto J, Ryhänen L, Tan EM (1981) Collagen: Its structure, function, and pathology. In: Fleischmayer R (ed) Progress in diseases of the skin, Grune & Stratton, New York, p 103-141.

Villani F, Bacchella L, Bulgheroni A, Pizzini L, Galimberti M, Aprile C & Luisetti M (1992) Study of functional and biochemical indicators of subclinical lung damage in bleomycin-treated patients. Resp Med 86: 327-333.

Wagenvoort CA (1980) Lung biopsy specimens in evaluation of pulmonary vascular disease. Chest 77: 614-625.

Watanabe Y, Yamaki K, Yamakawa I, Takagi K & Satake T (1985) Type III procollagen N-terminal peptides in experimental pulmonary fibrosis and human respiratory diseases. Eur J Respir Dis 67: 10-16.

Zhu GG, Puistola U, Risteli J, Risteli L, Kauppila A (1994) Type I and III procollagen metabolism and CA 125 in epithelial ovarian cancer. Int J Oncol 4: 669-674.

Åkesson A, Scheja A, Lundin A & Wollheim FA (1993) Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis & Rheumatism 37: 729-735.